Brand name authorized in: Austria Australia Canada Germany Spain France Ireland Italy Lithuania Netherlands Poland United Kingdom United States
The drug ADCIRCA contains one active pharmaceutical ingredient (API):
Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus cavernosum. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. Tadalafil has no effect in the absence of sexual stimulation.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This drug has been assigned below unique identifiers within the countries it is being marketed: